GlaxoSmithKline PLC ADR
I · Analyse IA
En bref
GSK develops and sells vaccines for diseases like RSV, shingles, flu, and HPV, plus specialty treatments for cancer, HIV, and respiratory conditions, and everyday medicines for asthma and infections [COMPANY OVERVIEW]. The company operates globally with manufacturing and research facilities, selling through hospitals, clinics, and pharmacies in over 100 countries. GSK also collaborates with partners like CureVac on mRNA vaccine technology and AN2 Therapeutics on tuberculosis therapies [COMPANY OVERVIEW].
GSK is a major UK-headquartered pharmaceutical company that makes vaccines (RSV, flu, shingles, meningitis), specialty medicines (oncology, HIV, respiratory), and general medicines (asthma, COPD, antibiotics) [COMPANY OVERVIEW]. With $32,7 billion in revenue and a 17,5% net margin, the company is financially healthy and generates $5,8 billion in free cash flow annually [Yahoo Finance]. Recent news shows Japan expanded approval for GSK's RSV vaccine Arexvy to younger at-risk adults, opening a larger market [Nasdaq].
GSK is financially strong with solid profitability, low debt, and healthy cash generation.
Score Sentinellis
7,9/10
En bonne santé financière
Capitalisation boursière
$102,4B
Chiffre d'affaires (12 mois)
GBP 32,7B
Explications
Comment nous lisons ces chiffres
Guides en langage clair · sans compte
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LirePiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LireAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LireII · Actualités récentes
Ce qui a fait bouger le cours
1 article · classés par pertinence
- Macro2026-05-18
GSK: Japan's MHLW Expands Eligible Population For Arexvy
Nasdaq
Premium · gratuit avec tout compte
Dodge & Cox, the second-largest institutional holder at 2,92% of the company, cut its stake by 14,4% in the most recent quarter, a meaningful reduction that could signal concerns about near-term performance or valuation [EODHD].
Risques
4
Opportunités
4
Signaux d'alerte
1
Direction
10
8 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de GlaxoSmithKline PLC ADR
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 4 opportunités et 1 signal d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
III · Entreprises similaires
À lire également
Même secteur · Santé — ou santé financière comparable
L'ajouter à votre liste ?